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Proteinase-activated receptors (PARs), a group of G protein-coupled receptors, are activated by the cleavage of their N-terminal domain by serine proteinases [1, 2] . The proteolytic cleavage of the N-terminal region of PARs unmasks a new N-terminal sequence that acts as a tethered ligand that binds and activates the receptor itself [1] . The PAR 2 subtype is highly expressed in the skin, is activated by trypsin and mast cell tryptase, and can be activated without the need for proteolysis by synthetic PAR 2 agonists, such as SLIGRL-NH 2 [1, 3] . Tryptase and PAR 2 are up-regulated on sensory nerves in the skin from atopic dermatitis patients [2] . Indeed, intradermal injections of SLIGRL-NH 2 evoke dose-dependent scratching in mice [4] . In addition, PAR 2 agonists induce the release of neuropeptide, such as substance P, from primary afferent neuron [5] . Pretreatment of mice with a histamine H 1 receptor antagonist, pyrilamine, has no effect on PAR 2 -mediated scratching [4] . These results indicate that PAR 2 signaling induces itching independently of histamine H 1 receptor signaling.
Olopatadine hydrochloride ((Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodinenz [b,e]oxepin-2-acetic acid monohydrochloride) is a second-generation antihistamine.
Olopatadine inhibits ear swelling and cytokine production in a murine chronic contact hypersensitivity model, while other antihistamines do not suppress them, suggesting that olopatadine exerts additional biological effects besides its blockade of histamine H 1 receptor [6] . In this study, we examined the effect of olopatadine on PAR 2 agonist-induced scratching behavior in mice.
Scratching behavior with a PAR 2 agonist was induced on the shaved neck of 6-8 weeks old C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME, USA) by subcutaneously injecting 50 l of a PAR 2 agonist 2f-LIGRL-amide (1 mg/ml in phosphate-buffered saline (PBS); Calbiochem, Dermstadt, Germany). Injected mice were individually transferred to cages for observation from one hour before subcutaneous injection for acclimatization. Room temperature was maintained at 22 to 25°C. Scratching behavior was counted as once when a hind leg of the animal touched the shaved area and returned to the ground, as previously described [4] . The number of scratching behavior was counted from -10 to 40 minutes 3 defining the time of administering the PAR 2 agonist as 0 minutes. The total number of scratching was the sum of scratching behavior from 0 to 30 minutes. Subcutaneous administration of PBS alone induced no scratching behavior in mice (data not shown). The skin sections stained with hematoxylin and eosin which was excised from shaved neck after 30 minutes of treatment with the PAR 2 agonist or PBS were used for histological evaluation.
We also examined expression levels of preprotachykinin A mRNA, the precursor for substance P, in the skin using quantitative real time polymerase chain reaction according to the manufacturer's instructions (Applied Biosystems, Forester City, CA, USA). In addition, immunohistochemical analysis of substance P using anti-substance P monoclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was done. Plasma levels of substance P were measured by a specific ELISA (R&D Systems, Mineapolis, MN, USA).
Olopatadine was orally given once at 1, 3, 10, or 30 mg/kg through a tube together with 1 ml of PBS 30 minutes before subcutaneous injection of the PAR 2 agonist. Pyrilamine (Sigma-Aldrich, St. Louis, MO, USA), a histamine H 1 receptor antagonist, was used to confirm that the PAR 2 agonist-induced scratching behavior is not mediated by histamine H 1 receptor. Pyrilamine (10 mg/kg) was subcutaneously injected into the hip of mice 30 minutes before the administration of the PAR 2 agonist. Furthermore, we examined the effect of olopatadine on the itch evoked by 150 μg of substance P (Peptide Institute, Osaka) treatment as the method for the PAR 2 agonist treatment. Mice orally given only PBS served as a control group.
The PAR 2 agonist induced scratching behavior just after the administration and its effect continued until 30 minutes after the administration ( Figure 1A ). The number of scratching behavior reached the maximum 5 minutes after the PAR 2 agonist administration at all groups and then decreased with time. Pretreatment with olopatadine significantly decreased the number of scratching behavior in mice treated at all doses compared with that in control mice.
In addition, inhibition of the number of scratching behavior was almost dependent on the dose of olopatadine. According to the skin hematoxylin and eosin staining pictures, the PAR 2 4 agonist treatment induced substantial cutaneous edema compared with PBS treatment, which was inhibited by olopatadine administration ( Figure 1C) . By contrast, the number of scratching behavior in the pyrilamine-pretreated group was comparable to that in the control group, suggesting that the inhibitory effect of olopatadine on the PAR 2 agonist-induced scratching behavior is not mediated by histamine H 1 receptor. Similar results were obtained for the total number of scratching that was the sum of scratching behavior from 0 to 30 minutes ( Figure 1B ).
Plasma levels of substance P increased by the PAR 2 agonist treatment ( Figure 2B ), though there were no significant differences in the skin preprotachykinin A mRNA expression levels ( Figure 2A ). However, secreted substance P could not be detected in the PAR 2 agonist-or PBS-treated skin. Although this discrepancy is unclear, it might be due to short half-life of substance P and/or high solubility of substance P in organic solvent, such as formaldehyde, and water which were used for the fixation and staining of skin samples [7] . Olopatadine preadministration inhibited elevation of plasma substance P levels induced by the PAR 2 treatment ( Figure 2B ). Furthermore, substance P treatment induced scratching behavior, which was inhibited by olopatadine pretreatment ( Figure 2C ).
Histamine is the important mediator of itching in allergic skin diseases [2] . However, it is well recognized in the routine clinical setting that itching of atopic dermatitis, nasal congestion in allergic rhinitis, and bronchial asthma do not always respond to H 1 antihistamines. Our finding that H 1 antihistamine, pyrilamine did not inhibit scratching induced by the PAR 2 agonist suggests that H 1 antihistamine-resistant itching is mediated in part by PAR 2 signaling. Furthermore, the significant inhibitory effect on PAR 2 -induced itching by olopatadine suggests that olopatadine may be effective for H 1 antihistamine-resistant itching.
Many studies have shown that olopatadine has various pharmacological and biological activities besides its histamine H 1 receptor antagonistic activity [6] . In particular, olopatadine suppresses release of neuropeptides, including substance P and calcitonin gene-related peptide, 5 from afferent neurons. Increased expression of substance P in the spinal dorsal horn following repeated hapten application is inhibited by olopatadine [8] . Olopatadine also attenuates the enhancement of capsaicin-induced substance P release by bradykinin from cultured dorsal root ganglion neurons [9] . Moreover, olopatadine decreases plasma levels of substance P in patients with atopic dermatitis, while cetiridine and fexofenadine do not decrease them [10] .
In this study, olopatadine inhibited the PAR 2 agonist-induced substance P secretion.
Furthermore, olopatadine decreased substance P-induced scratching behavior. Collectively, the inhibitory effect on PAR 2 -induced itching by olopatadine may be related to the inhibition of substance P release and substance P-induced itching by olopatadine, which is downstream of PAR 2 signaling.
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